Mary Laughlin

Mary Laughlin is a Board Certified Hematologist/Oncologist with expertise in immune-based cancer treatments.1 She currently serves as the Vice President and Head of Global Late Stage Clinical Development at ADC Therapeutics, a biopharmaceutical company.2

Professional Background

Mary Laughlin's professional experience includes:

• Current Role: Vice President, Head of Global Late Stage Clinical Development at ADC Therapeutics2
• Location: Based in New Providence, NJ, US2
• Education: SUNY at Buffalo1

Expertise and Specialization

Mary Laughlin's expertise lies in:

• Hematology and Oncology
• Immune-based cancer treatments
• Late-stage clinical development in the biopharmaceutical industry

Her role at ADC Therapeutics likely involves overseeing the development of advanced cancer therapies, particularly those in the later stages of clinical trials.

LinkedIn Profile

Mary Laughlin's LinkedIn profile can be found under the username mary-laughlin-a93b7737.1 This profile provides additional information about her professional background and experience in the field of oncology and drug development.